⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Sustained Improvements with Once-daily Valbenazine in Chorea Associated with Huntington’s Disease: Interim Results from a Long-term Open-label Study (S30.003)

Erin Furr Stimming Daniel O. Claassen Elise Kayson Jody Goldstein Sean C. Hinton Olga Klepitskaya Hui Zhang Grace Liang Dietrich Haubenberger

View Full Paper

Ask AI

Bookmark

Share

Abstract

To present interim analyses from KINECT®-HD2 (NCT04400331), an ongoing open-label study of once-daily valbenazine for chorea associated with Huntington's disease (HD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stimming et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db64358767740d https://doi.org/10.1212/wnl.0000000000204716

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management.2025
2A Wearable Movement Sensor Substudy of KINECT®-HD, a Phase 3 Trial of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease (P8-3.010)2024
3Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia2024 · 2 citations
4Tardive Dyskinesia With Chorea-Ballism Improved by Valbenazine: A Case Report2024
5Huntington Disease and Chorea2025 · 5 citations